How the FDA Determines Which Wellness Apps Are Regulated as Medical Devices

The FDA regulates digital health applications that qualify as medical devices if their intended use involves diagnosis, cure, mitigation, treatment or prevention of disease. Most general wellness applications that make no disease-related claims fall outside that oversight. The agency applies a risk-based framework, exercises enforcement discretion for many low-risk software functions, and operates a Digital Health Center of Excellence to clarify policy while supporting innovation.

In its guidance the FDA explains that it regulates software functions meeting the statutory definition of a device. [1] That evaluation looks beyond the delivery method. An app on a smartphone receives the same scrutiny as one on a wearable if the claims match the legal threshold.

General Wellness Apps Usually Escape Regulation

General wellness apps are not regulated as medical devices when claims relate only to maintaining or encouraging general health without referencing diseases. [1] An app that tracks steps to promote daily movement or suggests breathing exercises for relaxation often fits this category. It avoids medical language about symptoms or cures.

The distinction appears in real-world examples. One product might promote feeling more energetic through better habits. Another that promises to identify symptoms of a specific condition crosses into regulated territory.

The Digital Health Center of Excellence Guides the Process

The FDA launched the Digital Health Center of Excellence in September 2020 to advance digital health innovation and regulatory clarity. [1] This office compiles policy details, real-world examples and decision aids for companies building apps and software. It functions as a central hub for questions about where oversight starts and stops.

Staff track emerging technology patterns. They refresh resources and share flowcharts that map out typical developer scenarios.

Risk Shapes Oversight of Software as a Medical Device

The FDA applies risk-based oversight to Software as a Medical Device. [2] It directs more intense premarket review toward higher-risk SaMD functions while showing flexibility on lower-risk ones. This method matches the level of scrutiny to potential harm.

Many low-risk digital health tools receive enforcement discretion. The agency may choose not to enforce full requirements even if the software technically qualifies as a device. [2]

Specific Rules Cover Clinical Decision Support Tools

FDA guidance addresses clinical decision support software and spells out when it counts as a regulated device. [3] The document examines whether the tool drives a diagnosis or treatment decision or simply organizes information for a health professional to review.

International efforts through the IMDRF helped shape the FDA's thinking on these categories. [2] The resulting policies give developers clear pathways to evaluate their products.

What this means

The FDA's approach creates a clear separation between everyday wellness products and tools that carry targeted medical claims. Oversight hinges on intended use and risk level instead of the technology platform. Enforcement discretion for many low-risk functions eases demands on developers. The Digital Health Center of Excellence supplies self-assessment aids and ongoing policy updates drawn from primary documents.

Key takeaways

• The FDA regulates software functions if they are intended for diagnosis, treatment, or prevention of disease. [1]
• General wellness apps fall outside regulation when their claims avoid any reference to diseases or conditions. [1]
• The Digital Health Center of Excellence launched in September 2020 to improve regulatory clarity around digital tools. [1]
• Risk-based oversight for Software as a Medical Device directs stricter review to higher-risk functions. [2]
• The agency exercises enforcement discretion on many low-risk software functions. [2]

Limitations

FDA policies evolve with new guidance, legislation, and technological developments. This summary captures positions from the referenced primary documents but does not address every scenario or predict future updates. It does not constitute regulatory advice.

Sources / References

1. Digital Health Center of Excellence. U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/digital-health-center-excellence

2. Software as a Medical Device (SaMD). U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd

3. Clinical Decision Support Software. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software